Gingko raises $70M, plans NGS deployment against coronavirus

By LabPulse.com staff writers

May 28, 2020 -- Cell programming company Ginkgo Bioworks has announced $70 million in funding to use its technology to address the ongoing COVID-19 pandemic.

The financing round included new funding from Illumina as well as from prior backers General Atlantic and Viking Global Investors. Gingko will use the funds to scale its automation technologies and develop tools that use Illumina's next-generation sequencing (NGS) technology for tests that detect the novel coronavirus.

Illumina's NGS systems can simultaneously process thousands of tests, Gingko noted. The company intends to combine the NGS systems with its own hardware and software for automating biological experiments on a large scale. The combined technology could increase the volume of COVID-19 testing, according to Gingko.

In addition, Gingko is using its own funding to build a COVID-19 monitoring and diagnostic testing facility in its Boston Seaport labs. The labs will provide NGS-based testing with the goal of helping businesses and schools reopen. The company is already using its current NGS-based testing capacity to provide free support for public health departments across the U.S.

Grail raises $390M for multicancer liquid biopsy
Menlo Park, CA-based startup Grail has raised an additional $390 million to advance its multicancer blood test, which is being validated for the...
Illumina's revenue up, income down in Q1
Illumina reported a revenue increase in line with company guidance and a decline in net income in the first quarter of 2020, as it came to grips with...
Illumina sues BGI for patent infringement
Illumina has filed a patent infringement lawsuit against BGI, claiming that the company's CoolMPS products copied its proprietary sequencing-by-synthesis...
Illumina boasts record quarterly sequencing sales
Illumina reported record sales of sequencing systems and 10% revenue growth in the fourth quarter of 2019.
What's next for PacBio and Illumina?
The termination fee from Illumina provides Pacific Biosciences (PacBio) with as much or more than it would likely earn in revenue in 2020, notes Bruce...

Copyright © 2020 LabPulse.com

Last Updated ls 5/28/2020 3:56:53 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current